GlassScriptPhysician profile
Eunyoung Kim
NPI 1912455890
$4,398.94
in general payments reported to CMS, 2019-2025
37 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $375 · 2023: $720 · 2024: $1,355 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856 · Education: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.78 |
| Education | $578.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $434.28 | 2021-2025 | Rybrevant, Talvey, Darzalex |
| Daiichi Sankyo INC. | $382.10 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Seagen INC. | $369.97 | 2022-2025 | |
| Astellas Pharma US INC | $343.88 | 2023-2025 | Xtandi, Padcev, Vyloy |
| Pfizer INC. | $296.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $282.14 | 2023-2025 | Opdivo, Augtyro, Krazati |
| Incyte Corporation | $272.43 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Rigel Pharmaceuticals, INC. | $240.74 | 2021-2022 | |
| Lilly USA, LLC | $163.46 | 2021-2025 | Jaypirca, Verzenio |
| Regeneron Healthcare Solutions, INC. | $160.79 | 2023-2025 | Libtayo |
| Celgene Corporation | $148.48 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $141.99 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $111.12 | 2023-2025 | Fruzaqla, Iclusig, Advate |
| Astrazeneca Pharmaceuticals LP | $100.04 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Ipsen Biopharmaceuticals, INC | $97.95 | 2023-2025 | Onivyde, Tazverik |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $68.28 | 2024-2025 | |
| Genentech USA, INC. | $64.57 | 2023-2025 | Tecentriq, Alecensa, Phesgo |
| Exelixis INC. | $63.71 | 2021-2025 | Cabometyx |
| Emd Serono, INC. | $63.60 | 2023-2025 | Bavencio |
| Novartis Pharmaceuticals Corporation | $61.00 | 2021-2024 | |
| Abbvie INC. | $60.04 | 2024-2025 | |
| Global Blood Therapeutics, INC. | $56.13 | 2021-2022 | |
| Genmab U.S., INC. | $49.24 | 2025 | Tivdak, Epkinly |
| Eisai INC. | $49.18 | 2024-2025 | |
| Tersera Therapeutics LLC | $47.20 | 2025 | Zoladex |
| Sobi, INC | $39.53 | 2025 | |
| Jazz Pharmaceuticals INC. | $29.51 | 2025 | |
| Aveo Pharmaceuticals, INC. | $27.80 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.95 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $21.57 | 2023 | Xarelto |
| Amgen INC. | $20.77 | 2023 | Xgeva, Nplate |
| Kite Pharma, INC. | $20.06 | 2021 | |
| Puma Biotechnology, INC. | $19.19 | 2024 | |
| Glaxosmithkline, LLC. | $18.76 | 2025 | Jemperli |
| Servier Pharmaceuticals LLC | $18.59 | 2024 | |
| Immunocore Limited | $16.19 | 2024 | Kimmtrak |
| Springworks Therapeutics, INC. | $14.80 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunyoung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.